hydrochlorothiazide has been researched along with Left Ventricular Hypertrophy in 70 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a multi-center, single-arm, prospective study, we investigated the efficacy and safety of the fixed irbesartan/hydrochlorothiazide combination in Chinese patients with moderate to severe hypertension." | 9.17 | Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. ( Dai, QY; Huang, QF; Li, Y; Ma, GS; Sheng, CS; Wang, JG, 2013) |
| "The objective of this study was to compare valsartan or ramipril addition to amlodipine + hydrochlorothiazide (HCTZ) on blood pressure (BP) and left ventricular hypertrophy (LVH) in hypertensive diabetic patients with LVH." | 9.16 | Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| "Chlorthalidone (CTD) reduces 24-hour blood pressure more effectively than hydrochlorothiazide (HCTZ), but whether this influences electrocardiographic left ventricular hypertrophy is uncertain." | 9.15 | Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. ( Collins, G; Ernst, ME; Grimm, RH; Neaton, JD; Prineas, RJ; Soliman, EZ; Thomas, W, 2011) |
| "The aim of this trial was to examine the effects of antihypertensive fixed combination of lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd, Bosnia and Herzegovina) on regression of left ventricular hypertrophy in patients with essential arterial hypertension." | 9.13 | Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. ( Alekseevna Andrievskaja, S; Baraković, F; Begović, B; Buksa, M; Eduardovich Bagrij, A; Georgievich Voronkov, L; Gerc, V; Hima, F; Iosifovna Tchelujko, V; Ivanovich Dyaduk, A; Knezević, B; Kusljugić, Z; Lazarević, A; Musić, L; Nikolaevich Polivoda, S; Vataman, E; Vehabović, M, 2008) |
| "LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy." | 9.12 | Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2007) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 9.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| " This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension." | 9.10 | Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. ( Burns, D; Kleiman, J; Krause, S; Phillips, RA; Pitt, B; Reichek, N; Roniker, B; Willenbrock, R; Williams, GH; Zannad, F, 2003) |
| " After a 4-week placebo run-in period, 25 patients with mild-to-moderate essential hypertension were randomly allocated to active treatment with Losartan 50 mg titrated to Losartan 50 mg/hydrochlorothiazide (HCT) 12." | 9.09 | Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. ( Battegay, E; Dieterle, T; Martina, B; Weinbacher, M, 1999) |
| "This study evaluated the anti-hypertensive efficacy, tolerability and effects on left ventricular mass of losartan, a selective angiotensin II receptor antagonist, after 22 months in patients with essential hypertension." | 9.08 | Effects of losartan on hypertension and left ventricular mass: a long-term study. ( Aquino, D; di Salvo, G; Galzerano, D; Iacono, A; Iarussi, D; Limongelli, G; Mennella, S; Ratti, G; Tedesco, MA, 1998) |
| "The purpose of our study was to evaluate the antihypertensive efficacy, tolerability and effects on left ventricular mass of losartan over 10 months in patients with essential hypertension." | 9.08 | [The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension]. ( Acitorio, M; Aquino, D; Caccavale, A; Coppolino, P; Cosimi, R; Iacono, A; Iarussi, D; Ratti, G; Rocereto, A; Tedesco, MA, 1998) |
| "Enalapril was significantly more effective than hydrochlorothiazide in reversing left ventricular hypertrophy without negatively affecting left ventricular function." | 9.07 | Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. ( Dahlöf, B; Hansson, L, 1992) |
| "5 mg/day) on regression of left ventricular hypertrophy (LVH), an independent predictor of poor prognosis in hypertension, was compared by echocardiography to that of nifedipine (NFD, 40 mg/day), enalapril (ENL, 20 mg/day), atenolol (ATL, 100 mg/day), and hydrochlorothiazide (HCTZ, 25 mg/day) in four parallel double-blind studies in 151 hypertensive patients with a diastolic blood pressure between 95 and 120 mm Hg and a raised left ventricular mass index (LVMI) (mg/m2) (Devereux)." | 9.07 | Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. ( Amabile, G; Bory, M; De Luca, N; Denis, B; Imbs, JL; Lahiri, A; Marchegiano, R; Raftery, EB; Senior, R; Zannad, F, 1993) |
| " From evidence regarding potency, cardiovascular events, and electrolytes, we hypothesized a priori that 'CHIP' diuretics [CHlorthalidone, Indapamide and Potassium-sparing Diuretic/hydrochlorothiazide (PSD/HCTZ)] would rival RASIs for reducing LVM." | 8.98 | Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. ( Abdelfattah, R; Ernst, ME; Kostis, JB; Roush, GC; Sica, DA; Song, S, 2018) |
| "HCTZ use was associated with greater regression of ECG LVH and this effect was greater in patients on losartan- than atenolol-based therapy, independent of baseline severity of ECG LVH and hypertension and changes in BP." | 7.76 | Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2010) |
| "Twenty four hour blood pressure (BP) monitoring was carried out and structural state of left ventricular myocardium assessed in 20 patients with mild and moderate hypertension before and after 24 weeks of therapy with Hyzaar - fixed dose combination of losartan (50 mg) and hydrochlorothiazide (12." | 7.72 | [Therapy of patients with arterial hypertension with fixed dose combination of losartan and hydrochlorothiazide. Effect on 24 hour blood pressure and left-ventricular hypertrophy]. ( Chazova, IE; Dmitriev, VV; Ratova, LG; Sinitsin, VE; Stukalova, OV, 2003) |
| "It is indicated for the treatment of hypertension (including as initial therapy in severe hypertension) and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy (LVH)." | 6.45 | Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Keating, GM, 2009) |
| " In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8." | 5.17 | In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP, 2013) |
| "In a multi-center, single-arm, prospective study, we investigated the efficacy and safety of the fixed irbesartan/hydrochlorothiazide combination in Chinese patients with moderate to severe hypertension." | 5.17 | Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. ( Dai, QY; Huang, QF; Li, Y; Ma, GS; Sheng, CS; Wang, JG, 2013) |
| "The objective of this study was to compare valsartan or ramipril addition to amlodipine + hydrochlorothiazide (HCTZ) on blood pressure (BP) and left ventricular hypertrophy (LVH) in hypertensive diabetic patients with LVH." | 5.16 | Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| "Chlorthalidone (CTD) reduces 24-hour blood pressure more effectively than hydrochlorothiazide (HCTZ), but whether this influences electrocardiographic left ventricular hypertrophy is uncertain." | 5.15 | Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. ( Collins, G; Ernst, ME; Grimm, RH; Neaton, JD; Prineas, RJ; Soliman, EZ; Thomas, W, 2011) |
| "The aim of this trial was to examine the effects of antihypertensive fixed combination of lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd, Bosnia and Herzegovina) on regression of left ventricular hypertrophy in patients with essential arterial hypertension." | 5.13 | Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. ( Alekseevna Andrievskaja, S; Baraković, F; Begović, B; Buksa, M; Eduardovich Bagrij, A; Georgievich Voronkov, L; Gerc, V; Hima, F; Iosifovna Tchelujko, V; Ivanovich Dyaduk, A; Knezević, B; Kusljugić, Z; Lazarević, A; Musić, L; Nikolaevich Polivoda, S; Vataman, E; Vehabović, M, 2008) |
| "LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy." | 5.12 | Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2007) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 5.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| " This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension." | 5.10 | Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. ( Burns, D; Kleiman, J; Krause, S; Phillips, RA; Pitt, B; Reichek, N; Roniker, B; Willenbrock, R; Williams, GH; Zannad, F, 2003) |
| " After a 4-week placebo run-in period, 25 patients with mild-to-moderate essential hypertension were randomly allocated to active treatment with Losartan 50 mg titrated to Losartan 50 mg/hydrochlorothiazide (HCT) 12." | 5.09 | Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. ( Battegay, E; Dieterle, T; Martina, B; Weinbacher, M, 1999) |
| " To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months." | 5.09 | Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. ( Abrignani, MG; Barbagallo, M; Dominguez, LJ; Nardi, E; Novo, G; Novo, S; Strano, A, 2001) |
| "Patients with mild to moderate hypertension (diastolic blood pressure, 95 to 109 mm Hg) were randomly allocated to treatment with atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, or prazosin in a double-masked trial." | 5.08 | Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. ( Anderson, RJ; Gottdiener, JS; Massie, BM; Materson, BJ; Reda, DJ; Williams, DW, 1997) |
| "Patients with mild to moderate diastolic hypertension and LV mass in excess of 1 SD of normal values were randomized to isradipine (n = 89) or hydrochlorothiazide therapy (n = 45)." | 5.08 | Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. ( Chase, GA; Cushman, WG; Gottdiener, JS; Gottdiener, PS; Narayan, P; Papademetriou, V; Zachariah, PK, 1997) |
| "The purpose of our study was to evaluate the antihypertensive efficacy, tolerability and effects on left ventricular mass of losartan over 10 months in patients with essential hypertension." | 5.08 | [The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension]. ( Acitorio, M; Aquino, D; Caccavale, A; Coppolino, P; Cosimi, R; Iacono, A; Iarussi, D; Ratti, G; Rocereto, A; Tedesco, MA, 1998) |
| " The study included 175 (mean+/-SD age, 51+/-9 years) subjects with mild-moderate essential hypertension who had echocardiographic evidence of left ventricular (LV) hypertrophy taken from the SAMPLE study (Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation), an open-label multicenter study." | 5.08 | Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect: evidence from the sample study. ( Fogari, R; Mancia, G; Omboni, S; Palatini, P; Rappelli, A, 1998) |
| "The aim of this study was to evaluate the effect of the calcium antagonist Nifedipine GITS in a double-blind, randomized comparison with the diuretic hydrochlorothiazide (HCTZ) on reduction of left ventricular (LV) mass and minimal vascular resistance in a group of essential hypertensives with left ventricular hypertrophy (LVH)." | 5.08 | Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. ( Agabiti-Rosei, E; Corbellini, C; Monteduro, C; Muiesan, ML; Rizzoni, D; Salvetti, M; Zulli, R, 1998) |
| "This study evaluated the anti-hypertensive efficacy, tolerability and effects on left ventricular mass of losartan, a selective angiotensin II receptor antagonist, after 22 months in patients with essential hypertension." | 5.08 | Effects of losartan on hypertension and left ventricular mass: a long-term study. ( Aquino, D; di Salvo, G; Galzerano, D; Iacono, A; Iarussi, D; Limongelli, G; Mennella, S; Ratti, G; Tedesco, MA, 1998) |
| "In 174 patients with essential hypertension and left ventricular hypertrophy, enrolled in the Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation (SAMPLE), aged 20-65 years, we measured clinic blood pressure, 24 h ambulatory blood pressure and the left ventricular mass index (echocardiography) before and after treatment with lisinopril at 20 mg with the addition of 12." | 5.08 | The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. ( Agabiti-Rosei, E; Mancia, G; Omboni, S; Parati, G; Rizzoni, D, 1998) |
| "5 mg/day) on regression of left ventricular hypertrophy (LVH), an independent predictor of poor prognosis in hypertension, was compared by echocardiography to that of nifedipine (NFD, 40 mg/day), enalapril (ENL, 20 mg/day), atenolol (ATL, 100 mg/day), and hydrochlorothiazide (HCTZ, 25 mg/day) in four parallel double-blind studies in 151 hypertensive patients with a diastolic blood pressure between 95 and 120 mm Hg and a raised left ventricular mass index (LVMI) (mg/m2) (Devereux)." | 5.07 | Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. ( Amabile, G; Bory, M; De Luca, N; Denis, B; Imbs, JL; Lahiri, A; Marchegiano, R; Raftery, EB; Senior, R; Zannad, F, 1993) |
| "Enalapril was significantly more effective than hydrochlorothiazide in reversing left ventricular hypertrophy without negatively affecting left ventricular function." | 5.07 | Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. ( Dahlöf, B; Hansson, L, 1992) |
| " From evidence regarding potency, cardiovascular events, and electrolytes, we hypothesized a priori that 'CHIP' diuretics [CHlorthalidone, Indapamide and Potassium-sparing Diuretic/hydrochlorothiazide (PSD/HCTZ)] would rival RASIs for reducing LVM." | 4.98 | Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. ( Abdelfattah, R; Ernst, ME; Kostis, JB; Roush, GC; Sica, DA; Song, S, 2018) |
| "This review focuses on the role of the fixed-dose combination (FDC) drug valsartan/hydrochlorothiazide (HCTZ) in the treatment of hypertension." | 4.87 | Valsartan plus hydrochlorothiazide: a review of its use since its introduction. ( Bains, J; Smith, WB, 2011) |
| "HCTZ use was associated with greater regression of ECG LVH and this effect was greater in patients on losartan- than atenolol-based therapy, independent of baseline severity of ECG LVH and hypertension and changes in BP." | 3.76 | Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2010) |
| "Twenty four hour blood pressure (BP) monitoring was carried out and structural state of left ventricular myocardium assessed in 20 patients with mild and moderate hypertension before and after 24 weeks of therapy with Hyzaar - fixed dose combination of losartan (50 mg) and hydrochlorothiazide (12." | 3.72 | [Therapy of patients with arterial hypertension with fixed dose combination of losartan and hydrochlorothiazide. Effect on 24 hour blood pressure and left-ventricular hypertrophy]. ( Chazova, IE; Dmitriev, VV; Ratova, LG; Sinitsin, VE; Stukalova, OV, 2003) |
| "To investigate the effects of perindopril, propranolol, and dihydrochlorothiazide on artery wall thickening, left ventricular hypertrophy, and cardiac fibrosis in spontaneously hypertensive rats (SHR)." | 3.70 | Effects of perindopril, propranolol, and dihydrochlorothiazide on cardiovascular remodelling in spontaneously hypertensive rats. ( Chen, DG; Chen, SC; Rui, HB; Su, JZ; Wang, HJ; Wang, XY; Wu, KG, 1999) |
| "In hypertensive patients, left ventricular hypertrophy (LVH) may persist despite satisfactory blood pressure (BP) control." | 2.79 | Regression of Electrocardiographic Signs of Left Ventricular Hypertrophy by Combined Treatment With Thiazide Diuretic and Angiotensin-II Receptor Blocker. ( Fujiwara, H; Furukawa, Y; Kita, Y; Matsuda, M; Miyazaki, S; Sato, Y; Sawa, T; Takatsu, Y; Tanaka, M, 2014) |
| "The Assessment of Lotrel in Left Ventricular Hypertrophy and Hypertension Study compared a single-pill combination of amlodipine/benazepril at doses 5." | 2.74 | Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. ( Devereux, RB; Hall, D; Hilkert, R; Pitt, B; Purkayastha, D; Reichek, N; Rocha, RA, 2009) |
| "Reversal of left ventricular hypertrophy has been shown to improve left ventricular diastolic function in elderly patients with hypertension, but little is known about whether this affects physical performance." | 2.68 | Physical performance is preserved after regression of left ventricular hypertrophy. ( Cléroux, J; Lacourcière, Y; Poirier, L, 1997) |
| "Treatment with Enalapril decreased the reflection of the retinal arterial wall significantly and reduced the narrowing of arteries and arterio-venous crossing phenomena non-significantly." | 2.67 | Hypertensive retinal vascular changes: relationship to left ventricular hypertrophy and arteriolar changes before and after treatment. ( Dahlöf, B; Hansson, L; Stenkula, S, 1992) |
| "Irbesartan reduces left ventricular hypertrophy and increases probability of maintenance of sinus rhythm after cardioversion of atrial fibrillation." | 2.48 | [Irbesartan in clinical practice]. ( Malishevskiĭ, MV, 2012) |
| "It is indicated for the treatment of hypertension (including as initial therapy in severe hypertension) and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy (LVH)." | 2.45 | Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Keating, GM, 2009) |
| "Insulin resistance is associated with a number of risk factors for atherosclerosis, including glucose intolerance, hypertension, and dyslipidemia." | 2.38 | Insulin resistance. An often unrecognized problem accompanying chronic medical disorders. ( Bell, DS, 1993) |
| " In half of them the drug dosage can be reduced or the drug even discontinued." | 1.29 | [Decreasing the antihypertensive dosage during longterm treatment and complete regression of left ventricular hypertrophy]. ( Behr, U; Franz, IW; Ketelhut, R; Tönnesmann, U, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 26 (37.14) | 18.2507 |
| 2000's | 25 (35.71) | 29.6817 |
| 2010's | 19 (27.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roush, GC | 3 |
| Abdelfattah, R | 2 |
| Song, S | 2 |
| Kostis, JB | 2 |
| Ernst, ME | 4 |
| Sica, DA | 2 |
| Tadic, M | 1 |
| Cuspidi, C | 2 |
| Kuusela, PJ | 1 |
| Okura, T | 1 |
| Miyoshi, K | 1 |
| Irita, J | 1 |
| Enomoto, D | 1 |
| Jotoku, M | 1 |
| Nagao, T | 1 |
| Watanabe, K | 1 |
| Matsuoka, H | 1 |
| Ashihara, T | 1 |
| Higaki, J | 1 |
| Okin, PM | 4 |
| Hille, DA | 3 |
| Wiik, BP | 1 |
| Kjeldsen, SE | 6 |
| Lindholm, LH | 5 |
| Dahlöf, B | 8 |
| Devereux, RB | 9 |
| Huang, QF | 1 |
| Sheng, CS | 1 |
| Li, Y | 1 |
| Ma, GS | 1 |
| Dai, QY | 1 |
| Wang, JG | 3 |
| Buddharaju, V | 1 |
| Sawa, T | 1 |
| Sato, Y | 1 |
| Matsuda, M | 1 |
| Tanaka, M | 1 |
| Miyazaki, S | 1 |
| Furukawa, Y | 1 |
| Kita, Y | 1 |
| Takatsu, Y | 1 |
| Fujiwara, H | 1 |
| Goda, A | 1 |
| Masuyama, T | 1 |
| Gerc, V | 1 |
| Begović, B | 1 |
| Vehabović, M | 1 |
| Georgievich Voronkov, L | 1 |
| Vataman, E | 1 |
| Musić, L | 1 |
| Buksa, M | 1 |
| Kusljugić, Z | 1 |
| Baraković, F | 1 |
| Iosifovna Tchelujko, V | 1 |
| Ivanovich Dyaduk, A | 1 |
| Alekseevna Andrievskaja, S | 1 |
| Eduardovich Bagrij, A | 1 |
| Nikolaevich Polivoda, S | 1 |
| Lazarević, A | 1 |
| Knezević, B | 1 |
| Hima, F | 1 |
| Keating, GM | 1 |
| Reichek, N | 2 |
| Rocha, RA | 1 |
| Hilkert, R | 1 |
| Hall, D | 1 |
| Purkayastha, D | 1 |
| Pitt, B | 2 |
| Edelman, JM | 1 |
| Verdecchia, P | 1 |
| Angeli, F | 1 |
| Mazzotta, G | 1 |
| Reboldi, G | 1 |
| Yamada, Y | 1 |
| Tsuboi, K | 1 |
| Hattori, T | 1 |
| Murase, T | 1 |
| Ohtake, M | 1 |
| Furukawa, M | 1 |
| Ueyama, J | 1 |
| Nishiyama, A | 1 |
| Murohara, T | 1 |
| Nagata, K | 1 |
| Bains, J | 1 |
| Smith, WB | 1 |
| Kaplan, NM | 1 |
| Neaton, JD | 1 |
| Grimm, RH | 1 |
| Collins, G | 1 |
| Thomas, W | 1 |
| Soliman, EZ | 1 |
| Prineas, RJ | 1 |
| Fogari, R | 2 |
| Zoppi, A | 1 |
| Mugellini, A | 1 |
| Maffioli, P | 1 |
| Preti, P | 1 |
| Derosa, G | 1 |
| Malishevskiĭ, MV | 1 |
| Julius, S | 1 |
| Aurup, P | 1 |
| Edelman, J | 1 |
| Beevers, G | 1 |
| de Faire, U | 2 |
| Fyhrquist, F | 2 |
| Ibsen, H | 2 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 2 |
| Nieminen, MS | 3 |
| Omvik, P | 2 |
| Oparil, S | 2 |
| Snapinn, S | 1 |
| Wedel, H | 2 |
| Oikarinen, L | 1 |
| Toivonen, L | 1 |
| Viitasalo, M | 1 |
| Wachtell, K | 1 |
| Papademetriou, V | 4 |
| Jern, S | 1 |
| Baumgart, P | 1 |
| Willenbrock, R | 1 |
| Zannad, F | 2 |
| Phillips, RA | 1 |
| Roniker, B | 1 |
| Kleiman, J | 1 |
| Krause, S | 1 |
| Burns, D | 1 |
| Williams, GH | 1 |
| Ong, HT | 1 |
| Chazova, IE | 1 |
| Ratova, LG | 1 |
| Dmitriev, VV | 1 |
| Sinitsin, VE | 1 |
| Stukalova, OV | 1 |
| Galzerano, D | 2 |
| Tammaro, P | 1 |
| Cerciello, A | 1 |
| Breglio, R | 1 |
| Mallardo, M | 1 |
| Lama, D | 1 |
| Tuccillo, B | 1 |
| Capogrosso, P | 1 |
| Rinder, MR | 1 |
| Spina, RJ | 1 |
| Peterson, LR | 1 |
| Koenig, CJ | 1 |
| Florence, CR | 1 |
| Ehsani, AA | 1 |
| Boydak, B | 1 |
| Nalbantgil, S | 1 |
| Yilmaz, H | 1 |
| Zoghi, M | 1 |
| Ozerkan, F | 1 |
| Nalbantgil, I | 1 |
| Onder, R | 1 |
| Hedner, T | 1 |
| Narkiewicz, K | 1 |
| Westendorp, B | 1 |
| Schoemaker, RG | 1 |
| van Gilst, WH | 1 |
| van Veldhuisen, DJ | 1 |
| Buikema, H | 1 |
| Xie, HH | 1 |
| Shen, FM | 1 |
| Zhang, XF | 1 |
| Jiang, YY | 1 |
| Su, DF | 1 |
| Cooper-Dehoff, R | 1 |
| Cohen, JD | 1 |
| Bakris, GL | 1 |
| Messerli, FH | 1 |
| Erdine, S | 1 |
| Hewkin, AC | 1 |
| Kupfer, S | 1 |
| Pepine, CJ | 1 |
| Harris, KE | 1 |
| Sládková, M | 1 |
| Kojsová, S | 1 |
| Jendeková, L | 1 |
| Pechánová, O | 1 |
| López, B | 1 |
| Castellano, JM | 1 |
| González, A | 1 |
| Barba, J | 1 |
| Díez, J | 1 |
| Narayan, P | 3 |
| Kokkinos, P | 1 |
| Senior, R | 1 |
| Imbs, JL | 1 |
| Bory, M | 1 |
| Amabile, G | 1 |
| Denis, B | 1 |
| De Luca, N | 1 |
| Marchegiano, R | 1 |
| Lahiri, A | 1 |
| Raftery, EB | 1 |
| Lumme, JA | 1 |
| Jounela, AJ | 1 |
| Kirpizidis, HG | 1 |
| Papazachariou, GS | 1 |
| Bell, DS | 1 |
| Staessen, J | 1 |
| Amery, A | 1 |
| Marmor, A | 1 |
| Schneeweiss, A | 1 |
| Franz, IW | 1 |
| Behr, U | 1 |
| Ketelhut, R | 1 |
| Tönnesmann, U | 1 |
| Gottdiener, JS | 3 |
| Reda, DJ | 1 |
| Massie, BM | 1 |
| Materson, BJ | 1 |
| Williams, DW | 1 |
| Anderson, RJ | 1 |
| Lacourcière, Y | 1 |
| Poirier, L | 1 |
| Cléroux, J | 1 |
| Kribben, A | 1 |
| Anlauf, M | 1 |
| Distler, A | 1 |
| Gärtner, H | 1 |
| Holzgreve, H | 1 |
| Michaelis, J | 1 |
| Röcker, L | 1 |
| Schäfers, R | 1 |
| Philipp, U | 1 |
| Wellek, S | 1 |
| Philipp, T | 1 |
| Cushman, WG | 1 |
| Zachariah, PK | 1 |
| Gottdiener, PS | 1 |
| Chase, GA | 1 |
| Tedesco, MA | 2 |
| Ratti, G | 2 |
| Aquino, D | 2 |
| Caccavale, A | 1 |
| Acitorio, M | 1 |
| Rocereto, A | 1 |
| Cosimi, R | 1 |
| Coppolino, P | 1 |
| Iarussi, D | 2 |
| Iacono, A | 2 |
| Roman, MJ | 1 |
| Alderman, MH | 1 |
| Pickering, TG | 1 |
| Pini, R | 1 |
| Keating, JO | 1 |
| Sealey, JE | 1 |
| Omboni, S | 3 |
| Parati, G | 2 |
| Palatini, P | 2 |
| Vanasia, A | 1 |
| Muiesan, ML | 2 |
| Mancia, G | 3 |
| Rappelli, A | 1 |
| Agabiti-Rosei, E | 2 |
| Zulli, R | 1 |
| Salvetti, M | 1 |
| Rizzoni, D | 2 |
| Corbellini, C | 1 |
| Monteduro, C | 1 |
| Limongelli, G | 1 |
| di Salvo, G | 1 |
| Mennella, S | 1 |
| Thürmann, PA | 1 |
| Martina, B | 1 |
| Dieterle, T | 1 |
| Weinbacher, M | 1 |
| Battegay, E | 1 |
| Brilla, CG | 1 |
| Su, JZ | 1 |
| Chen, SC | 1 |
| Wu, KG | 1 |
| Chen, DG | 1 |
| Rui, HB | 1 |
| Wang, XY | 1 |
| Wang, HJ | 1 |
| Sareli, P | 2 |
| Radevski, IV | 1 |
| Valtchanova, ZP | 1 |
| Libhaber, E | 2 |
| Candy, GP | 1 |
| Den Hond, E | 1 |
| Libhaber, C | 1 |
| Skudicky, D | 2 |
| Staessen, JA | 2 |
| Novo, S | 1 |
| Abrignani, MG | 1 |
| Novo, G | 1 |
| Nardi, E | 1 |
| Dominguez, LJ | 1 |
| Strano, A | 1 |
| Barbagallo, M | 1 |
| Schiffrin, EL | 1 |
| Park, JB | 1 |
| Pu, Q | 1 |
| Candy, G | 1 |
| Radevski, I | 1 |
| Valtchanova, Z | 1 |
| Tshele, E | 1 |
| Thijs, L | 1 |
| Palmieri, V | 1 |
| Hansson, L | 2 |
| Stenkula, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension[NCT00139555] | Phase 4 | 125 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060] | Phase 4 | 53 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects[NCT00388388] | Phase 2 | 1 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Few subjects recruited, sponsor withdrew support.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | micrograms/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline (PINP) | 12 Months (PINP) | Baseline (PIIINP) | 12 Months (PIIINP) | Baseline (ICTP) | 12 Months (ICTP) | |
| Placebo Control | 2.1 | 0.6 | 4.5 | 1.6 | 2.5 | -2.3 |
| Spironolactone | 2.1 | 0.7 | 4.7 | 2.0 | 2.2 | 2.7 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | millimeters (Mean) | |
|---|---|---|
| Left Atrial Dimension (Baseline) | Left Atrial Dimension (12-Month Follow-Up) | |
| Placebo Control | 41 | 40 |
| Spironolactone | 40 | 40 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | mm/m^2 (Mean) | |
|---|---|---|
| LVED Cavity Size (Baseline) | LVED Cavity Size (12-Month Follow-Up) | |
| Placebo Control | 145 | 146 |
| Spironolactone | 133 | 129 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | millimeters (Mean) | |
|---|---|---|
| Maximum Left Ventricular Wall Thickness (Baseline) | Maximum Left Ventricular Wall Thickness (12-Month Follow-Up) | |
| Placebo Control | 21 | 19 |
| Spironolactone | 22 | 22 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Percentage of Total LV Mass (Mean) | |
|---|---|---|
| LGE Assessment of Myocardial Fibrosis (Baseline) | LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up) | |
| Placebo Control | 2.5 | 2.8 |
| Spironolactone | 1.1 | 1.8 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Peak VO2 (Baseline) | Peak VO2 (12-Month Follow-Up) | |
| Placebo Control | 28 | 29 |
| Spironolactone | 30 | 29 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| NYHA Class (Baseline) | NYHA Class (12-Month Follow Up) | |
| Placebo Control | 1.5 | 1.6 |
| Spironolactone | 1.6 | 1.7 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Ratio (Mean) | |
|---|---|---|
| Diastolic Function (Baseline) | Diastolic Function (12-month Follow-Up) | |
| Placebo Control | 15 | 13 |
| Spironolactone | 14 | 13 |
8 reviews available for hydrochlorothiazide and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Diuretics, Potassium Spari | 2018 |
Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics, Potassium Sparing; Drug Therapy, | 2018 |
Is chlorthalidone better than hydrochlorothiazide in reducing cardiovascular events in hypertensives?
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2013 |
Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Diuretics; Drug Combinati | 2009 |
Valsartan plus hydrochlorothiazide: a review of its use since its introduction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Diuretics; Drug Combinati | 2011 |
[Irbesartan in clinical practice].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2012 |
Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.
Topics: Acanthosis Nigricans; Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteri | 1993 |
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atenolol; Calcium Channe | 2002 |
45 trials available for hydrochlorothiazide and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Comparison of the effect of combination therapy with an angiotensin II receptor blocker and either a low-dose diuretic or calcium channel blocker on cardiac hypertrophy in patients with hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Th | 2013 |
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; D | 2013 |
Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Albuminuria; Antihypertensive Agents; Asian People; Biphenyl Compounds; Blo | 2013 |
Regression of Electrocardiographic Signs of Left Ventricular Hypertrophy by Combined Treatment With Thiazide Diuretic and Angiotensin-II Receptor Blocker.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Drug Therapy, Combination; Electro | 2014 |
Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy | 2008 |
Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; | 2009 |
Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Combined Modality Therapy; Diuretics | 2011 |
The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hyd | 2012 |
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind M | 2012 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; F | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2004 |
Comparison of effects of exercise and diuretic on left ventricular geometry, mass, and insulin resistance in older hypertensive adults.
Topics: Aged; Angiotensins; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Compo | 2004 |
The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Ch | 2004 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2007 |
Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Biomarkers; | 2007 |
Effects of diltiazem, metoprolol, enalapril and hydrochlorothiazide on frequency of ventricular premature complexes.
Topics: Analysis of Variance; Antihypertensive Agents; Cardiac Complexes, Premature; Diltiazem; Echocardiogr | 1994 |
Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Female; France; Humans; Hydro | 1993 |
Left ventricular mass, serum electrolyte levels and cardiac arrhythmias in patients with mild hypertension treated with cilazapril or hydrochlorothiazide.
Topics: Cardiac Complexes, Premature; Cilazapril; Double-Blind Method; Echocardiography; Electrocardiography | 1993 |
Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients: a double-blind study.
Topics: Blood Pressure; Blood Pressure Determination; Double-Blind Method; Drug Therapy, Combination; Echoca | 1995 |
APTH--a trial on ambulatory blood pressure monitoring and treatment of hypertension: objectives and protocol.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Blood Pressure Monitors; Dipeptid | 1993 |
[Changes in the left ventricular mass, wall tension and left atrial filling in long-term antihypertensive therapy. A comparative study with cilazapril and a thiazide diuretic].
Topics: Aged; Blood Pressure; Cardiac Volume; Cilazapril; Diastole; Double-Blind Method; Echocardiography; F | 1993 |
Effect of hydrochlorothiazide therapy on cardiac arrhythmias in African-American men with systemic hypertension and moderate to severe left ventricular hypertrophy.
Topics: Black or African American; Diuretics; Echocardiography; Electrocardiography; Electrocardiography, Am | 1996 |
Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhib | 1997 |
Physical performance is preserved after regression of left ventricular hypertrophy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combin | 1997 |
Hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment. Influence on LVH, proteinuria and metabolic parameters. The HANE Trial Research Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Ant | 1997 |
Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Double-Blind Method; E | 1997 |
[The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Diuretics; Double-Blind Method; Female; Humans; Hydrochlorothi | 1998 |
Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitoring, Am | 1998 |
Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 1998 |
Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect: evidence from the sample study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Re | 1998 |
Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delayed-Action Prepa | 1998 |
Effects of losartan on hypertension and left ventricular mass: a long-term study.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hype | 1998 |
The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastol | 1998 |
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Female; Huma | 1999 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Drug | 1999 |
Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; | 1999 |
Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black Pe | 2001 |
Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Blood | 2001 |
Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihyper | 2002 |
Relationship between treatment-induced changes in left ventricular mass and blood pressure in black african hypertensive patients: results of the Baragwanath Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Blood Pressure; Body Mass Index; Calcium Cha | 2002 |
Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Echocardiography; Enalapril; Heart; Humans; Hydroc | 1992 |
Hypertensive retinal vascular changes: relationship to left ventricular hypertrophy and arteriolar changes before and after treatment.
Topics: Adult; Antihypertensive Agents; Arterioles; Child; Double-Blind Method; Echocardiography; Enalapril; | 1992 |
17 other studies available for hydrochlorothiazide and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Diuretics and left ventricular hypertrophy regression: The relationship that we commonly forget.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Hyper | 2018 |
Interventricular vessel of the heart and diuretics.
Topics: Chlorthalidone; Diuretics; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, | 2019 |
Left ventricular hypertrophy as a target of treatment in patients with hypertension.
Topics: Angiotensin Receptor Antagonists; Electrocardiography; Humans; Hydrochlorothiazide; Hypertrophy, Lef | 2014 |
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardio | 2010 |
Is hydrochlorothiazide more effective on LVH in nonresponders to losartan than in those to atenolol?
Topics: Antihypertensive Agents; Atenolol; Electrocardiography; Humans; Hydrochlorothiazide; Hypertrophy, Le | 2010 |
Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Dr | 2011 |
Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Electrocardiography; Humans; Hydrochlorothiazide | 2011 |
[LIFE study proves preventive action. With losartan to do even more against stroke].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Co | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther | 2003 |
[Therapy of patients with arterial hypertension with fixed dose combination of losartan and hydrochlorothiazide. Effect on 24 hour blood pressure and left-ventricular hypertrophy].
Topics: Adult; Aged; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochl | 2003 |
Angiotensin receptor blockers and endpoint protection.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Creatinine; Drug Therapy, Combination; | 2005 |
Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Aorta; Atenolol; Baroreflex; Biphenyl Compounds; Blood Pressure; C | 2006 |
Chronic and acute effects of different antihypertensive drugs on femoral artery relaxation of L-NAME hypertensive rats.
Topics: Acetylcholine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pre | 2007 |
[Decreasing the antihypertensive dosage during longterm treatment and complete regression of left ventricular hypertrophy].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Echocardiography; Exercis | 1996 |
Renin-angiotensin system mediated mechanisms: cardioreparation and cardioprotection.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Female; Fibrosis; Heart Failure; Human | 2000 |
Effects of perindopril, propranolol, and dihydrochlorothiazide on cardiovascular remodelling in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Age | 1999 |